BD-9136

BD-9136 is an experimental small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, including BRD2, BRD3, and BRD4. Developed primarily as a research tool, it functions as an epigenetic modulator by binding to the bromodomains of these proteins, thereby preventing their interaction with acetylated histones and inhibiting the transcription of oncogenic and metabolic genes. In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), BD-9136 has been shown to sensitize tumor cells to chemotherapy, such as gemcitabine, by disrupting amino acid metabolism and suppressing in vivo tumor growth. Its development is focused on identifying therapeutic targets and overcoming drug resistance in lethal cancers like PDAC.